Triple oral anti-diabetic therapy in type 2 diabetes

Diabetic Medicine, Supplement

Volumn 20, Issue 1, 2003, Pages 14-16

  Barnett, A H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; INSULIN; SULFONYLUREA DERIVATIVE;

BLOOD GLUCOSE MONITORING; HUMAN; INSULIN TREATMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT PARTICIPATION; PRACTICE GUIDELINE; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT PLANNING; ARTICLE; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; MALE; MIDDLE AGED; TREATMENT REFUSAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT REFUSAL;

EID: 28244441939     PISSN: 14665468     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. National Institute for Clinical Excellence. Guidance on Rosiglitazone for Type 2 Diabetes Mellitus, Section 1.2, no. 9. August 2000.
2. Murphy E, Nolan JJ. What is the role of the thiazolidinediones (glitazones) in clinical practice? In Barnett AH ed. Diabetes Annual. London: Martin Dunitz Ltd, 2002; 119-140.
3. Avandia: rosiglitazone maleate tablets. Package labelling insert. Philadelphia: SmithKline Beecham Pharmaceuticals, 1999.
4. Actos: pioglitazone hydrochloride tablets. Package labelling insert. Lincolnshire, USA: Takeda Pharmaceuticals America, 1999.
5. Jones N, Jones T, Menci L, Xu J, Freed M, Kreider M. Rosiglitazone in combination with glibenclamide plus metformin is effective and well tolerated in type 2 diabetes patients. Diabetologia 2001; 44 (Suppl. 1) A235, Abstr. 904.
6. Morjaria HK, Lawrence IG, Jarvis J, McNally PG, Davies MJ. Clinical effectiveness of pioglitazone in triple combination oral hypoglycaemic therapy in type 2 diabetes mellitus. Diabet Med 2002; 19: 42.
7. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycaemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
9. Bakris GL, Dole JF, Porter LA et al. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000; 49: A388.
10. Freed MI, Weston WM, Viberti G. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. Diabetologia 1999; 42: A230.
11. Nakamura T, Ushiyama C, Shimada N, Hayaski K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000; 14: 250-254.